close

Fundraisings and IPOs

Date: 2017-01-04

Type of information: Private placement

Company: Clovis Oncology (USA - CO)

Investors:

Amount: $175 million

Funding type: private placement

Planned used:

  • Clovis Oncology intends to use the net proceeds of the offering for general corporate purposes, including commercial planning and sales and marketing expenses associated with the launch of Rubraca™ (rucaparib) in the United States and, if approved by the European Medicines Agency (EMA), in Europe, funding of its development programs, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital.

Others:

  • • On January 4, 2017, Clovis Oncology announced that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 750,000 shares. The offering, including the sale of the additional shares, is expected to close on January 9, 2017, subject to customary closing conditions.
  • • On January 3, 2017, Clovis Oncology announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $175 million. All shares of the common stock to be sold in the offering will be offered by Clovis Oncology. J. P. Morgan Securities LLC and BofA Merrill Lynch are acting as joint book-running managers for the offering. Stifel and SunTrust Robinson Humphrey are acting as co-managers for the offering.
  • In addition, Clovis Oncology intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares sold on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
 

Therapeutic area: Cancer - Oncology

Is general: Yes